Return to homepagePandemic Pact

SARS-CoV-2 Nanogel Sublingual Vaccine

Grant number: RF-TAA-2020-V05

Grant search

Key facts

  • Disease

    COVID-19

  • Start & end year

    2020
    2021

  • Known Financial Commitments (USD)

    $335,428.84

  • Funder

    RIGHT Foundation

  • Principal Investigator

    Chang Seon Song

  • Research Location

    41

  • Lead Research Institution

    KCAV

  • Research Priority Alignment

    N/A

  • Research Category

    Vaccines research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    Innovation

  • Study Type

    Non-Clinical

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Not Applicable

  • Vulnerable Population

    Not applicable

  • Occupations of Interest

    Not applicable

Abstract

Development of a COVID19 vaccine based on the optimal combination of recombinant antigens (seven candidates representing S1, RBD, NP) identified from Korean COVID19 patients combined with an inactivated Lactobacillus spp. nanogel adjuvant for sublingual delivery.